Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Tempest Therap. From $0.23 to $9.77 in 1 day
View:
Post by Noteable on Oct 12, 2023 9:31am

Tempest Therap. From $0.23 to $9.77 in 1 day

4,247% increase in share price from October 10th to October 11,  2023
Comment by Noteable on Oct 12, 2023 9:37am
Shares of Tempest Therapeutics Inc. TPST soared nearly 4,000% on Wednesday after the company released study results for its investigational cancer treatment TPST-1120 in patients with liver cancer.   The drug candidate, in combination with the Roche Holding AG RHHBY treatments Tecentriq and Avastin, showed clinical superiority as a first-line treatment for unresectable or metastatic ...more  
Comment by Noteable on Oct 12, 2023 11:16am
Tempest Phase Ib/II study is being run by Roche, which is responsible for managing the operations of the trial. https://www.biospace.com/article/tempest-s-stock-skyrockets-4-000-percent-on-early-data-for-hepatocellular-carcinoma-/
Comment by inthno on Oct 12, 2023 11:32am
Hey Note and thanks for the Tempest study results....Problem is and really makes no sense is how this company could go up that much with the results and then try to compare the pela results general responses in comparison and Tempest is up 4000% and ONC is down almost 50% from our year high. Just seems way out of whack especially considering the idication onc is trying to beat and with The Pan Can ...more  
Comment by fox7mf on Oct 12, 2023 11:52am
Many of these investors refuse to hold MC accountable for anything. This situation is deplorable and we continue to be kept in the dark. Some here even say share price doesn't matter, lol. GL everyone. 
Comment by Angler101 on Oct 12, 2023 12:53pm
Hey Fox.....take a look a Tempest Therapeutic’s stock price history for just the last 4 months.....they drifted slowly from about $1.20 all the way down to .23 cents since July!......and then.....BOOM.....the share price really is totally irrelevant...the share price can be easily manipulated.....there was no reason for Tempest’s epic fall from $1.20 to .23, in light of all the amazing trial ...more  
Comment by fox7mf on Oct 12, 2023 1:42pm
SP matters when management can't create shareholder value. Nobody knows about Oncy because of a deficient sales team. What, are we hoping for a 4000% day now, lol? Defecate in one hand, hope in the other...the posters here who are lashing out at my posts are doing so because they too are frustrated and losing confidence. So be it...good luck all.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities